Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Prudential PLC

Prudential PLC reduced its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 36.3% in the second quarter, according to its most recent filing with the SEC. The fund owned 29,528 shares of the medical equipment provider's stock after selling 16,854 shares during the period. Prudential PLC's holdings in Lantheus were worth $2,371,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. UMB Bank n.a. grew its stake in Lantheus by 161.4% in the 1st quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 247 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Lantheus by 184.1% in the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock valued at $26,000 after purchasing an additional 208 shares during the period. Principal Securities Inc. bought a new position in Lantheus in the fourth quarter worth approximately $28,000. Fidelis Capital Partners LLC bought a new position in Lantheus in the first quarter worth approximately $34,000. Finally, FinTrust Capital Advisors LLC raised its position in Lantheus by 53.6% during the 1st quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider's stock valued at $41,000 after purchasing an additional 232 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company's stock.

Insiders Place Their Bets

In related news, CAO Andrea Sabens sold 341 shares of Lantheus stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $123.15, for a total value of $41,994.15. Following the completion of the sale, the chief accounting officer now directly owns 62,216 shares in the company, valued at approximately $7,661,900.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CAO Andrea Sabens sold 341 shares of the firm's stock in a transaction on Monday, July 15th. The stock was sold at an average price of $123.15, for a total value of $41,994.15. Following the completion of the transaction, the chief accounting officer now owns 62,216 shares in the company, valued at approximately $7,661,900.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mary Anne Heino sold 10,481 shares of the business's stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $95.50, for a total value of $1,000,935.50. Following the sale, the director now owns 454,923 shares in the company, valued at approximately $43,445,146.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 40,852 shares of company stock valued at $3,922,001. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Stock Up 2.0 %

NASDAQ:LNTH traded up $2.08 during midday trading on Thursday, reaching $104.03. 797,382 shares of the stock traded hands, compared to its average volume of 1,027,761. The business has a 50-day moving average of $103.89 and a two-hundred day moving average of $82.22. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89. The stock has a market capitalization of $7.21 billion, a PE ratio of 15.88 and a beta of 0.50.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The business had revenue of $394.10 million for the quarter, compared to analysts' expectations of $382.12 million. During the same quarter in the prior year, the company posted $1.40 EPS. The business's revenue for the quarter was up 22.5% on a year-over-year basis. On average, equities analysts forecast that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on LNTH shares. JMP Securities dropped their price target on Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 1st. Leerink Partners raised their target price on shares of Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a research report on Thursday, July 11th. Truist Financial reduced their price target on shares of Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a report on Thursday, August 1st. Redburn Atlantic initiated coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They set a "buy" rating and a $175.00 price objective on the stock. Finally, B. Riley boosted their price objective on shares of Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a research note on Thursday, July 25th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Lantheus presently has a consensus rating of "Moderate Buy" and an average target price of $126.00.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.